Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

GIANT BIOGENE HOLDING CO., LTD

巨子生物控股有限公司

(An exempted company incorporated in the Cayman Islands with limited liability)

(Stock code: 2367)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Giant Biogene Holding Co., Ltd (the "**Company**") on a voluntary basis.

The Company is pleased to announce that Shaanxi Giant Biotechnology Co., Ltd., a wholly-owned subsidiary of the Company, has received the Medical Device Registration Certificate of the People's Republic of China (Registration Certificate No.: Guo Xie Zhu Zhun 20263130044) issued by China National Medical Products Administration in respect of the product titled Recombinant Type I α1 Subtype Collagen and Sodium Hyaluronate Composite Solution (the "**Product**") today. With recombinant collagen and sodium hyaluronate as its main ingredient, the Product is indicated for intradermal injection to improve skin smoothness of the cheeks.

This Product is the world's first recombinant collagen and sodium hyaluronate composite solution implant product for improving cheek smoothness, officially approved through the joint review by the Medical Device Evaluation and Drug Evaluation divisions.

Following the Recombinant Type I α1 Subtype Collagen Freeze-dried Fibers, the successful approval of this product further expands the product matrix of the Company, reflects our continued leading technology R&D and industrial capabilities. It also unlocks broader market space, injecting new growth momentum into the Company's business development in the field of skin rejuvenation. In the future, the Company will steadily promote the market promotion and launch of the above-mentioned products, provide differentiated solutions to consumer needs in more scenarios through diversified product portfolio, comprehensive channel networks, and refined brand operations, and continuously strengthen the Company's leading market position in the field of health and beauty.

Shareholders and potential investors of the Company are reminded to exercise caution when dealing in the shares of the Company.

By order of the Board
Giant Biogene Holding Co., Ltd
Yan Jianya
Chairman of the Board

Xi'an, the PRC, 15 January 2026

As of the date of this announcement, the Board comprises Mr. Yan Jianya, Ms. Ye Juan, Ms. Fang Juan, Ms. Zhang Huijuan and Ms. Yan Yubo as executive directors, and Mr. Huang Jin, Mr. Shan Wenhua and Ms. Wong Sze Wing as independent non-executive directors.